Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 10, 2026

Robust Trading, IB Fee Growth to Support Morgan Stanley's Q1 Earnings

View original at finance.yahoo.com
Robust Trading, IB Fee Growth to Support Morgan Stanley's Q1 Earnings Morgan Stanley MS is slated to announce first-quarter 2026 earnings on April 15 before the opening bell…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Companies acknowledged that volatility is part of life and they will have to do business around it, unlike last year when tariff announcements led to deal drought

    60% confidence
  • Morgan Stanley's first-quarter revenues are expected to reach $19.88 billion, suggesting 12.1% year-over-year growth

    60% confidence
  • Morgan Stanley's earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, with the average beat being 18.19%

    60% confidence
  • Morgan Stanley's Q1 2026 earnings are estimated at $3.08 per share, indicating an 18.5% increase from the prior-year quarter

    60% confidence
  • Total underwriting fees are estimated at $1.06 billion, implying a 6.7% rise

    60% confidence
  • Advisory fees are expected to be $883.7 million, indicating a 51.6% year-over-year jump

    60% confidence
  • Equity trading revenues are estimated at $4.74 billion, suggesting a 15% rise from the prior-year quarter

    60% confidence
  • Net interest revenues are estimated at $2.58 billion, suggesting a 9.7% year-over-year rise

    60% confidence
  • Equity underwriting fees are estimated at $395.2 million, suggesting 23.9% year-over-year growth

    60% confidence
  • Investment banking income is expected to reach $2.02 billion, indicating a 29.5% year-over-year jump

    60% confidence
  • Fixed-income underwriting fees are estimated at $667.3 million, indicating a 1.4% fall

    60% confidence
  • Fixed-income trading revenues are estimated at $2.9 billion, indicating an 11.2% gain

    60% confidence
  • Management expects net interest income in the wealth management segment to rise modestly on a sequential basis

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com